6533b7d1fe1ef96bd125c1bf

RESEARCH PRODUCT

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

Timothy HardyKristy WondersRamy YounesGuruprasad P AithalRocio AllerMichael AllisonPierre BedossaFay BetsouJerome BoursierM Julia BrosnanAlastair BurtJeremy CobboldHelena Cortez-pintoChris P DayJean-francois DufourMattias EkstedtSven FrancqueStephen HarrisonLuca MielePatrik NasrGeorge PapatheodoridisSalvatore PettaDina TiniakosRichard TorstensonLuca ValentiAdriaan G HolleboomHannele Yki-jarvinenAndreas GeierManuel Romero-gomezVlad RatziuElisabetta BugianesiJörn M SchattenbergQuentin M. AnsteeLitmus Consortium

subject

Liver CirrhosisPROGNOSISCirrhosisSCORING SYSTEM[SDV]Life Sciences [q-bio]PROGRESSIONDiseaseBiomarker Cirrhosis NAFLD NASHSTEATOHEPATITISDEFINITIONSCohort Studies0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasePharmacology (medical)030212 general & internal medicineLongitudinal StudiesRegistriesComputingMilieux_MISCELLANEOUSmedia_commonPharmacology. TherapyFatty liverLiver NeoplasmsNASHGeneral Medicine3. Good healthCirrhosisLiver317 PharmacyCohort0305 other medical scienceCohort studymedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAGeriatrikQUESTIONNAIRENAFLD; NASH; Cirrhosis; Biomarker610 Medicine & health03 medical and health sciencesNAFLDmedicineSTEATOSISmedia_common.cataloged_instanceHumansALGORITHMEuropean unionIntensive care medicine030505 public healthbusiness.industryCONSUMPTIONBiomarkerSTAGING SYSTEMmedicine.diseaseDiabetes Mellitus Type 2Geriatrics3121 General medicine internal medicine and other clinical medicine3111 BiomedicineHuman medicineSteatohepatitisbusinessBiomarker; Cirrhosis; NAFLD; NASH

description

© 2020 The Author(s).

10.1016/j.cct.2020.106175https://hal.univ-angers.fr/hal-03284343